Augmented Reality: How CAR T-Cell Therapy Works

: 0 Comments

Chimeric Antigen Receptor T-cell Therapy or CAR T-cell therapy is an immunotherapy where a patient's immune system t-cells are engineered to detect and kill cancer cells. Currently there are four FDA approved CAR T-cell therapies for blood cancers:

  • Axicabtagene ciloleucel (YescartaTM) is FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. It is a CD19-directed genetically modified autologous T cell immunotherapy. You can read more about this drug here.
  • Brexucabtagene autoleucel (Tecartus®) is FDA approved for for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. You can read more about this drug here.
  • Tisagenlecleucel (KymriahTM) is FDA approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Limitation of Use: Kymriah is not indicated for treatment of patients with primary central nervous system lymphoma. It is a CD19-directed genetically modified autologous T cell immunotherapy. You can read more about this drug here.
  • Tocilizumab (Actemra®) is approved for the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). You can read more about this drug here.

Additional clinical trials are underway. For more information about clinical trials, please contact an Information Specialist at 1-800-955-4572. Click HERE to learn more about CAR T-cell therapy.

LLS presents an augmented reality experience to help patients and caregivers understand the process of CAR T-Cell Therapy from collection through infusion. Using an app and your mobile device's camera, you can place the augmented reality video on any background and interact to help you better understand each step of this innovative treatment process. You can scan the QR codes below to access your app store or you can visit HERE to learn more.

Sign in or Register to view comments.